Literature DB >> 28484052

Chronic Critical Illness from Sepsis Is Associated with an Enhanced TCR Response.

Farina Borken1, Robby Markwart1, Robert P Requardt1, Katja Schubert1, Michal Spacek2, Miroslav Verner2, Stefan Rückriem2, André Scherag1,3, Frank Oehmichen2, Frank M Brunkhorst1,4,5, Ignacio Rubio6,7.   

Abstract

Sepsis is characterized by a disproportionate host response to infection that often culminates in multiple organ failure. Current concepts invoke a deregulated immune reaction involving features of hyperinflammation, as well as protracted immune suppression. However, owing to the scarcity of human data, the precise origin of a long-term suppression of adaptive immunity remains doubtful. We report on an explorative clinical study of chronic critical illness (CCI) patients aimed at assessing the long-term consequences of sepsis on T cell function. Blood was drawn from 12 male CCI patients (median age 67 y, range 48-79 y) receiving continuous mechanical ventilation and renal replacement therapy in a long-term care hospital who had been treated in an external acute care hospital for severe sepsis. T cells were purified and subjected to flow cytometric immune-phenotyping and functional assays. We found that T cells from CCI patients featured higher basal levels of activation and stronger expression of the inhibitory surface receptor programmed cell death 1 compared with controls. However, T cells from CCI patients exhibited no suppressed TCR response at the level of proximal TCR signaling (activation/phosphorylation of PLCγ, Erk, Akt, LAT), activation marker upregulation (CD69, CD25, CD154, NUR77), IL-2 production, or clonal expansion. Rather, our data illustrate an augmented response in T cells from CCI patients in response to TCR/coreceptor (CD3/CD28) challenge. Thus, the present findings reveal that CCI sepsis patients feature signs of immune suppression but that their T cells exhibit a primed, rather than a suppressed, phenotype in their TCR response, arguing against a generalized T cell paralysis as a major cause of protracted immune suppression from sepsis.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28484052     DOI: 10.4049/jimmunol.1700142

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity.

Authors:  Isaac J Jensen; Frances V Sjaastad; Thomas S Griffith; Vladimir P Badovinac
Journal:  J Immunol       Date:  2018-03-01       Impact factor: 5.422

Review 2.  Advances in the understanding and treatment of sepsis-induced immunosuppression.

Authors:  Fabienne Venet; Guillaume Monneret
Journal:  Nat Rev Nephrol       Date:  2017-12-11       Impact factor: 28.314

3.  Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation.

Authors:  Elena G Novoselova; Sergey M Lunin; Olga V Glushkova; Maxim O Khrenov; Svetlana B Parfenyuk; Nadezhda M Zakharova; Evgeny E Fesenko
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

4.  Identification of key miRNA‑mRNA pairs in septic mice by bioinformatics analysis.

Authors:  Jianxin Chen; Min Lin; Sen Zhang
Journal:  Mol Med Rep       Date:  2019-08-20       Impact factor: 2.952

5.  CD28 Agonism Improves Survival in Immunologically Experienced Septic Mice via IL-10 Released by Foxp3+ Regulatory T Cells.

Authors:  Yini Sun; Jianfeng Xie; Jerome C Anyalebechi; Ching-Wen Chen; He Sun; Ming Xue; Zhe Liang; Kristen N Morrow; Craig M Coopersmith; Mandy L Ford
Journal:  J Immunol       Date:  2020-11-06       Impact factor: 5.422

6.  Long-term survivors of murine sepsis are predisposed to enhanced LPS-induced lung injury and proinflammatory immune reprogramming.

Authors:  Scott J Denstaedt; Angela C Bustamante; Michael W Newstead; Bethany B Moore; Theodore J Standiford; Rachel L Zemans; Benjamin H Singer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-06-23       Impact factor: 6.011

Review 7.  HDL and persistent inflammation immunosuppression and catabolism syndrome.

Authors:  Grant Barker; Julia R Winer; Faheem W Guirgis; Srinivasa Reddy
Journal:  Curr Opin Lipidol       Date:  2021-10-01       Impact factor: 4.616

Review 8.  Sepsis therapies: learning from 30 years of failure of translational research to propose new leads.

Authors:  Jean-Marc Cavaillon; Mervyn Singer; Tomasz Skirecki
Journal:  EMBO Mol Med       Date:  2020-03-16       Impact factor: 12.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.